



## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)

**Date:** February 11, 2021

**Time:** 12:00 PM to 4:00 PM

**Agenda:** To review and evaluate grant applications

**Place:** National Institutes of Health  
National Institute on Drug Abuse  
301 North Stonestreet Avenue  
Bethesda, MD 20892  
(Virtual Meeting)

**Contact Person:** Trinh T. Tran, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
Division of Extramural Research  
National Institute on Drug Abuse, NIH  
301 North Stonestreet Avenue, MSC 6021  
Bethesda, MD 20892  
(301) 827-5843  
[trinh.tran@nih.gov](mailto:trinh.tran@nih.gov)

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)

**Date:** February 17, 2021

**Time:** 1:00 PM to 4:00 PM

**Agenda:** To review and evaluate grant applications

**Place:** National Institutes of Health  
National Institute on Drug Abuse  
301 North Stonestreet Avenue  
Bethesda, MD 20892  
(Virtual Meeting)

**Contact Person:** Gerald L. McLaughlin, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
National Institute on Drug Abuse, NIH  
301 North Stonestreet Avenue, MSC 6021  
Bethesda, MD 20892  
(301) 827-5819  
gm145a@nih.gov

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)

**Date:** February 18, 2021

**Time:** 12:00 PM to 3:00 PM

**Agenda:** To review and evaluate grant applications

**Place:** National Institutes of Health  
National Institute on Drug Abuse  
301 North Stonestreet Avenue  
Bethesda, MD 20892  
(Virtual Meeting)

**Contact Person:** Ipolia R. Ramadan, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
Division of Extramural Research  
National Institute on Drug Abuse, NIH  
301 North Stonestreet Avenue, MSC 6021  
Bethesda, MD 20892  
(301) 827-4471  
ramadanir@mail.nih.gov

**Name of Committee:** National Institute on Drug Abuse Special Emphasis Panel NIDA Centers Review

**Date:** February 26 - March 1, 2021

**Time:** 10:00 AM to 5:30 PM

**Agenda:** To review and evaluate grant applications

**Place:** National Institutes of Health  
National Institute on Drug Abuse  
301 North Stonestreet Avenue  
Bethesda, MD 20892  
(Virtual Meeting)

**Contact Person:** Ipolia R Ramadan, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
Division of Extramural Research  
National Institute on Drug Abuse, NIH  
301 North Stonestreet Avenue, MSC 6021  
Bethesda, MD 20892  
(301) 827-4471  
ramadanir@mail.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist  
Development Award for Clinicians, Scientist Development Awards, and Research Scientist  
Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279,  
Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: January 8, 2021.

**Tyeshia M. Roberson,**

*Program Analyst,*

*Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-00574 Filed: 1/13/2021 8:45 am; Publication Date: 1/14/2021]